MAGE-A-Targeted Immunotherapy Competitor Analysis 2018 – ResearchAndMarkets.com

Source: MAGE-A-Targeted Immunotherapy Competitor Analysis 2018 – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Competitor
Analysis: MAGE-A-Targeted Immunotherapy” report has been added
to ResearchAndMarkets.com’s offering.

This Competitive Intelligence report analyzes the competitive field of MAGE-A-Targeted
Immunotherapies as of June 2018 in a tabulated format with
structured listings of industry-relevant data.

Melanoma Associated Antigens A (MAGE-A) are expressed
in a variety of cancers of diverse histological origin and germinal
cells. MAGE-A were the first human tumor-associated antigens identified
at the molecular level. They belong to the larger family of
cancer/testis antigens (CTA), whose expression is consistently detected
in cancers of different histological origin and germinal cell. The
MAGE-A sub-family includes 12 highly homologous genes located on
chromosome Xq28.

Specific gene products have been identified by immunohistochemistry in
cancers of different histological origin, including high percentages of
non-small cell lung cancers (NSCLC), bladder cancers, esophageal and
head and neck cancers, and sarcomas. These antigens are also frequently
expressed in triple negative breast cancers, myeloma, and Reed-Sternberg
cells in Hodgkin’s disease, with the highest frequency being detected in
synovial sarcoma.

Among healthy tissues, the expression of specific members of the family
has been observed in spermatogonia, placenta, and fetal ovary. However,
recently, MAGE-A1 and -A12 genes have been shown to be expressed in CNS.
Preferential intracellular location may be different for different
antigens, e.g., mostly cytoplasmic for MAGE-A1, -A3, and -A4, but mostly
nuclear for MAGE-A10. Due to their relatively high tumor specificity,
they represent attractive targets for active specific and adoptive
cancer immunotherapies.

The report includes a compilation of currently active projects in
research and development of vaccines, TCR-engineered T-cells, Cytotoxic
T-Lymphocytes /CTLs) and oncolytic viruses targeting melanoma associated
antigen A (MAGE-A). In addition, the report lists company- and
institution-specific R&D pipelines of MAGE-A-Targeted
Immunotherapies.

Key Topics Covered:

1. MAGE-A-Targeted Immunotherapy:

• MAGE-A1
• MAGE-A3
• MAGE-A4
• MAGE-A6
• MAGE-A10
• MAGE-A12

2. Corporate & Institutional MAGE-A Immunotherapy R&D Pipelines

For more information about this report visit https://www.researchandmarkets.com/research/kcnblb/mageatargeted?w=4

Published at Thu, 21 Jun 2018 20:13:49 +0000